Skip to main content

Table 2 2-Way ANOVAs assessing (A) the interaction between obesity and co-morbid conditions on coronary dilations and (B) the interaction between obesity and commonly prescribed medications on coronary dilations

From: Obesity and statins are both independent predictors of enhanced coronary arteriolar dilation in patients undergoing heart surgery

A   
Interaction with obesity F test P value
Diabetes 0.043 0.836
Hypertension 0.587 0.447
Coronary artery disease 1.714 0.195
Hypercholesterolemia 3.634 0.061
Coronary artery bypass grafting 0.023 0.880
Aortic valve replacement 0.033 0.856
B   
Interactions with obesity F test P value
ACE - Inhibitor 7.469 0.008
Angiotensin receptor blocker 3.801 0.056
Aspirin 0.081 0.777
Statin 3.923 0.052
Insulin 2.196 0.144
Oral anti-diabetic drug 0.186 0.668
Beta blocker 7.581 0.008
Diuretic 1.513 0.224
Calcium channel blocker 0.904 0.345
H+ blocker 0.449 0.505
Nitrate 0.864 0.356
  1. ACE – angiotensin converting enzyme inhibitor, Degrees of freedom and the error of degrees of freedom all have values of 1 and 60, respectively.